ARGENT

Advanced Radiotherapy, Generated by Exploiting Nanoprocesses and Technologies

 Coordinatore CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE 

 Organization address address: Rue Michel -Ange 3
city: PARIS
postcode: 75794

contact info
Titolo: Ms.
Nome: Véronique
Cognome: Debisschop
Email: send email
Telefono: +33 1 69823272
Fax: +33 1 69823333

 Nazionalità Coordinatore France [FR]
 Totale costo 3˙656˙454 €
 EC contributo 3˙656˙454 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-ITN
 Funding Scheme MC-ITN
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2018-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 Organization address address: Rue Michel -Ange 3
city: PARIS
postcode: 75794

contact info
Titolo: Ms.
Nome: Véronique
Cognome: Debisschop
Email: send email
Telefono: +33 1 69823272
Fax: +33 1 69823333

FR (PARIS) coordinator 683˙525.84
2    AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

 Organization address address: CALLE SERRANO 117
city: MADRID
postcode: 28006

contact info
Titolo: Ms.
Nome: María ángeles
Cognome: López Vázquez
Email: send email
Telefono: 34915681462
Fax: 34915681573

ES (MADRID) participant 739˙806.38
3    THE OPEN UNIVERSITY

 Organization address address: WALTON HALL
city: MILTON KEYNES
postcode: MK7 6AA

contact info
Titolo: Dr.
Nome: Louise
Cognome: Thomas
Email: send email
Telefono: +44 1908 858509
Fax: +44 1908654192

UK (MILTON KEYNES) participant 608˙797.62
4    QUEEN'S UNIVERSITY BELFAST

 Organization address address: University Road
city: BELFAST
postcode: BT7 1NN

contact info
Titolo: Mrs.
Nome: Colleen
Cognome: Spence
Email: send email
Telefono: +44 28 9097 5183
Fax: +44 28 9097 5182

UK (BELFAST) participant 483˙863.03
5    CHEMATECH SAS

 Organization address address: RUE DU BAS DE CHANOT 7
city: CHEVIGNY SAINT SAUVEUR
postcode: 21800

contact info
Titolo: Dr.
Nome: Frédéric
Cognome: Boschetti
Email: send email
Telefono: 33380396110
Fax: +33 3 80 39 61 17

FR (CHEVIGNY SAINT SAUVEUR) participant 255˙948.66
6    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Mr.
Nome: Jean-Christophe
Cognome: Coste
Email: send email
Telefono: 33169089097
Fax: 33169082199

FR (PARIS 15) participant 255˙948.66
7    NANOH SAS

 Organization address address: PLACE DE L'EUROPE 2, PARC D'ACTIVITES GVIO 2, BAT A
city: SAINT QUENTIN FALLAVIER
postcode: 38070

contact info
Titolo: Dr.
Nome: Cedric
Cognome: Louis
Email: send email
Telefono: +33 6 9916 8784

FR (SAINT QUENTIN FALLAVIER) participant 255˙948.66
8    GSI HELMHOLTZZENTRUM FUER SCHWERIONENFORSCHUNG GMBH

 Organization address address: PLANCKSTRASSE 1
city: DARMSTADT
postcode: 64291

contact info
Titolo: Ms.
Nome: Heike
Cognome: Kühlen
Email: send email
Telefono: 496160000000
Fax: 496160000000

DE (DARMSTADT) participant 253˙454.74
9    QuantumWise A/S

 Organization address address: LERSO PARKALLE 107
city: Copenhagen
postcode: 2100

contact info
Titolo: Mrs.
Nome: Nanna
Cognome: Fock
Email: send email
Telefono: +45 69901888
Fax: +45 69802801

DK (Copenhagen) participant 119˙160.41
10    JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN

 Organization address address: GRUNEBURGPLATZ 1
city: FRANKFURT AM MAIN
postcode: 60323

contact info
Titolo: Prof.
Nome: Andrey
Cognome: Solov'yov
Email: send email
Telefono: +49 6979847507

DE (FRANKFURT AM MAIN) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

million    generation    hadron    cancer    nanoscale    radiotherapy    induced    treatment    therapies    create    patients    enhanced   

 Obiettivo del progetto (Objective)

Cancer, the second most common form of death after cardiovascular disease, is a major European health concern. In 2006, 3.1 million new cases were diagnosed and 1.7 million deaths were attributed to cancer within Europe. The European Commission has a “European Partnership for Action against Cancer” (IP/09/1380) with the aim of reducing the number of cancer cases by 15% by 2020. A key challenge is to “Develop a more coordinated approach to cancer-related research across Europe”. Around 50% of patients receive radiotherapy as part of their cancer treatment and it is second only to surgery in its ability to cure cancer. However, radiotherapy is limited by the effects induced in the surrounding healthy tissues strongly, which very harmful for the patients. New approaches that enhance radiosensitivity within tumours have the potential to provide a major impact on the delivery of radiotherapy to patients. Two of the most promising approaches (hadron and nanoparticles-enhanced therapies) are driven by nanoscale phenomena. This proposal brings together world-leading researchers from the academic and private sectors aim at developing hadron and NP-enhanced therapies, united by the common purpose of optimising radiotherapy by understanding and exploiting nanoscale processes induced by radiation. Such an understanding will open a new era in which radiotherapy is revolutionised to provide more successful cancer treatment with subsequent economic and ‘quality of life’ benefits for the EU population as a whole. The main objective of this intersectoral and multidisciplinary ITN is to create a new generation of researchers and experts able to create the platform on which next-generation cancer therapy will be built. The consortium aims to train a cohort of 13 ESRs to subsequently act as leaders and ambassadors in the field.

Altri progetti dello stesso programma (FP7-PEOPLE)

NK IN PREGNANCY (2013)

Impact of Natural Killer Cells on Fetal and Placental Development

Read More  

NOVEL KIDNEY MODEL (2013)

zebrafish model to study human hypertension

Read More  

DDR-MYCN-NB (2012)

The DNA damage response pathway in MYCN amplified neuroblastoma

Read More